Study completed in collaboration with
James Madison University reveals new
ways to address menstrual-related symptoms with cannabis
SMITHS FALLS, ON, March 22, 2022 /CNW/ - Canopy Growth
Corporation's ("Canopy Growth" or the "Company") (TSX: WEED)
(NASDAQ: CGC) scientific research team has announced positive
results from a six-month, randomized clinical trial studying the
effects of cannabidiol (CBD) on menstrual-related symptoms. This
study was conducted in collaboration with Dr. Jessica G. Irons and Morgan L. Ferretti at James
Madison University in Harrisonburg, Virginia. Nearly 75% of
reproductive-aged menstruating individuals report experiencing
unpleasant menstrual-related symptoms, ranging from cramping and
bloating to back pain and shifts in mood including irritability and
stress. This study marks the first exploration of the effects of
cannabinoids for symptom management.
Over the course of six months, 40 participants who experienced
moderate to severe menstrual-related symptoms were randomized to
receive 160mg or 320mg of CBD, in divided doses twice daily for 5
days each month beginning the first day they experienced symptoms.
Results showed significantly reduced menstrual-related symptoms
over the 6 months relative to a one-month baseline, and the higher
dose was also effective in significantly reducing irritability and
stress over the same period. The data collected from this study is
the first of its kind to demonstrate the efficacy of cannabis-based
therapies to treat symptoms experienced by individuals, including
those related to menstruation.
"Our findings showed that CBD improves a variety of physical and
psychological symptoms associated with menstruation and can be
consumed in a targeted way around an individual's menstrual cycle,"
shared Dr. Marcel O. Bonn-Miller,
Canopy Growth's Vice President, Human & Animal Research.
"Studies have shown that individuals report using cannabis to help
manage their menstrual-related symptoms – however no study had been
conducted that examined the efficacy of cannabinoids in this
Future research may be conducted to uncover the effectiveness of
CBD at managing symptoms during and individual's reproductive
phases of life and beyond, as Canopy Growth continues exploring
promising, yet under-explored applications of cannabis.
Canopy is proud to offer consumers in Canada and the United States a wide range of CBD product
offerings, from leading brands like Tweed, Spectrum Therapeutics,
and Martha Stewart CBD (availability varies by region).
About Canopy Growth
Canopy Growth (TSX:WEED,NASDAQ:CGC) is a world-leading diversified
cannabis and cannabinoid-based consumer product company, driven by
a passion to improve lives, end prohibition, and strengthen
communities by unleashing the full potential of cannabis.
Leveraging consumer insights and innovation, we offer product
varieties in high-quality dried flower, oil, softgel capsule,
infused beverage, edible, and topical formats, as well as vaporizer
devices by Canopy Growth and industry-leader Storz & Bickel.
Our global medical brand, Spectrum Therapeutics, sells a range of
full-spectrum products using its colour-coded classification system
and is a market leader in both Canada and Germany. Through our award-winning Tweed and
Tokyo Smoke banners, we reach our adult-use consumers and have
built a loyal following by focusing on top quality products and
meaningful customer relationships. Canopy Growth has entered into
the health and wellness consumer space in key markets including
Canada, the United States, and Europe through BioSteel sports nutrition, and
This Works skin and sleep solutions; and has introduced additional
hemp derived CBD products to the United
States through our First & Free and Martha Stewart CBD
brands. Canopy Growth has an established partnership with Fortune
500 alcohol leader Constellation Brands. For more information visit
Notice Regarding Forward-Looking Information
This press release contains "forward-looking statements" and
"forward-looking information" within the meaning of applicable U.S.
and Canadian securities laws (collectively, "forward-looking
statements"), which involve certain known and unknown risks and
uncertainties. Forward-looking statements predict or describe our
future operations, business plans, business and investment
strategies and the performance of our investments. These
forward-looking statements are generally identified by their use of
such terms and phrases as "intend," "goal," "strategy," "estimate,"
"expect," "project," "projections," "forecasts," "plans," "seeks,"
"anticipates," "potential," "proposed," "will," "should," "could,"
"would," "may," "likely," "designed to," "foreseeable future,"
"believe," "scheduled" and other similar expressions. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date the statement was made.
Forward-looking statements are necessarily based upon a number of
estimates and assumptions that, while considered reasonable by
management, are inherently subject to significant business,
economic and competitive risks, financial results, results,
performance or achievements expressed or implied by those
forward-looking statements and the forward-looking statements are
not guarantees of future performance. Accordingly, there are or
will be important factors that could cause actual outcomes or
results to differ materially from those indicated in these
statements. A discussion of some of the material factors applicable
to Canopy Growth Corporation ("Canopy") can be found under the
section entitled "Risk Factors" in Canopy's Annual Report on Form
10-K for the year ended March 31,
2021, filed with the Securities and Exchange Commission and
with applicable Canadian securities regulators, as such factors may
be further updated from time to time in its periodic filings with
the Securities and Exchange Commission and with applicable Canadian
securities regulators, which can be accessed at
www.sec.gov/edgar and www.sedar.com, respectively. These
factors should not be construed as exhaustive and should be read in
conjunction with the other cautionary statements that are included
in this press release and in the filings. Any forward-looking
statement included in this press release is made as of the date of
this press release and, except as required by law, Canopy disclaims
any obligation to update or revise any forward-looking statement.
Readers are cautioned not to put undue reliance on any
forward-looking statement. Forward-looking statements contained in
this press release are expressly qualified by this cautionary
SOURCE Canopy Growth Corporation